Taiwan
· Delayed Price · Currency is TWD Acepodia Company Description
Acepodia, Inc. operates as a clinical stage biotechnology company.
The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care.
It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies.
In addition, the company develops ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in preclinical study; ACE1708; and ACE1702 targeting HER2 that is in phase 1 clinical trial.
Acepodia Inc. has strategic clinical collaboration with Pfizer Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases.
The company is based in Grand Cayman, the Cayman Islands.
| Country | Cayman Islands |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Shih-Chia Hsiao |
Contact Details
Address: Ugland House Grand Cayman, KY1-1104 Cayman Islands | |
| Website | acepodia.com |
Stock Details
| Ticker Symbol | 6976 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | KYG0073G1091 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shih-Chia Hsiao Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Yuhmin Yang Ph.D. | Co-Founder, Chairman and Chief Strategy Officer |
| Leo OuYang | Senior Director of Accounting and Financial Officer |
| YanDa Lai | Director of Operations |
| Yajun Wang Ph.D. | Chief Technical Officer, Chief Quality Officer and Vice President of Quality |
| Jessica Lee M.B.A., M.S. | Head of Business Development |
| Stephanie Hsiao | Secretary |